CY1112505T1 - Ανοσοκατασταλτικες ενωσεις και συνθεσεις - Google Patents
Ανοσοκατασταλτικες ενωσεις και συνθεσειςInfo
- Publication number
- CY1112505T1 CY1112505T1 CY20121100286T CY121100286T CY1112505T1 CY 1112505 T1 CY1112505 T1 CY 1112505T1 CY 20121100286 T CY20121100286 T CY 20121100286T CY 121100286 T CY121100286 T CY 121100286T CY 1112505 T1 CY1112505 T1 CY 1112505T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compositions
- immunosuppressive compounds
- diseases
- immunosuppressant
- prevention
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C323/31—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/32—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton having at least one of the nitrogen atoms bound to an acyclic carbon atom of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Abstract
Η παρούσα εφεύρεση σχετίζεται με ανοσοκατασταλτικά, τη διαδικασία για την παρασκευή τους, τις χρήσεις τους και τις φαρμακευτικές συνθέσεις που τα περιέχουν. Η εφεύρεση παρέχει μια νέα κατηγορία ενώσεων χρήσιμων στη θεραπεία ή στην πρόληψη ασθενειών ή διαταραχών που προκαλούνται από λεμφικές αλληλεπιδράσεις, συγκεκριμένα ασθένειες οι οποίες σχετίζονται με τη μεταγωγή σήματος μέσω του υποδοχέα ΕDG.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US47193103P | 2003-05-19 | 2003-05-19 | |
EP04752678A EP1638551B1 (en) | 2003-05-19 | 2004-05-19 | Immunosuppressant compounds and compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1112505T1 true CY1112505T1 (el) | 2015-12-09 |
Family
ID=33476902
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121100286T CY1112505T1 (el) | 2003-05-19 | 2012-03-16 | Ανοσοκατασταλτικες ενωσεις και συνθεσεις |
Country Status (18)
Country | Link |
---|---|
US (2) | US7462629B2 (el) |
EP (1) | EP1638551B1 (el) |
JP (1) | JP4575920B2 (el) |
CN (4) | CN1791395B (el) |
AT (1) | ATE537825T1 (el) |
AU (2) | AU2004240649A1 (el) |
BR (1) | BRPI0410454A (el) |
CA (1) | CA2524054C (el) |
CY (1) | CY1112505T1 (el) |
DK (1) | DK1638551T3 (el) |
ES (1) | ES2379169T3 (el) |
HK (1) | HK1090559A1 (el) |
MX (1) | MXPA05012459A (el) |
PL (1) | PL1638551T3 (el) |
PT (1) | PT1638551E (el) |
SI (1) | SI1638551T1 (el) |
WO (1) | WO2004103309A2 (el) |
ZA (1) | ZA200508203B (el) |
Families Citing this family (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004010949A2 (en) * | 2002-07-30 | 2004-02-05 | University Of Virginia Patent Foundation | Compounds active in spinigosine 1-phosphate signaling |
KR101186386B1 (ko) * | 2003-08-29 | 2012-09-26 | 오노 야꾸힝 고교 가부시키가이샤 | S1p 수용체 결합능을 갖는 화합물 및 그 의약 용도 |
WO2005041899A2 (en) * | 2003-11-03 | 2005-05-12 | University Of Virginia Patent Foundation | Orally available sphingosine 1-phosphate receptor agonists and antagonists |
TW200538433A (en) * | 2004-02-24 | 2005-12-01 | Irm Llc | Immunosuppressant compounds and compositiions |
WO2005082841A1 (en) * | 2004-02-24 | 2005-09-09 | Irm Llc | Immunosuppressant compounds and compositions |
PL1772145T3 (pl) * | 2004-07-16 | 2011-08-31 | Kyorin Seiyaku Kk | Sposób skutecznego stosowania leku i sposób dotyczący zapobiegania efektom ubocznym |
US7795472B2 (en) | 2004-10-12 | 2010-09-14 | Kyorin Pharmaceutical Co., Ltd. | Process for producing 2-amino-2-[2-[4-(3-benzyloxyphenylthio)-2-chlorophenyl]ethyl]-1,3-propanediol hydrochloride and hydrates thereof, and intermediates in the production thereof |
CA2590748A1 (en) * | 2004-12-06 | 2006-06-15 | University Of Virginia Patent Foundation | Aryl amide sphingosine 1-phosphate analogs |
KR101262400B1 (ko) * | 2004-12-13 | 2013-05-08 | 오노 야꾸힝 고교 가부시키가이샤 | 아미노카르복실산 유도체 및 그 의약 용도 |
AU2006212866A1 (en) * | 2005-02-08 | 2006-08-17 | Novartis Ag | Antilymphocyte antibody induction by combination of an S1P receptor agonist/modulator and of immunosuppressive drugs |
BRPI0607435A2 (pt) | 2005-02-14 | 2010-04-06 | Univ Virginia | composto ou um sal ou éster farmaceuticamente aceitável do mesmo, e, uso de um composto |
CN101203512A (zh) * | 2005-04-22 | 2008-06-18 | 第一三共株式会社 | 杂环化合物 |
MX2008002540A (es) * | 2005-08-23 | 2008-03-14 | Irm Llc | Compuestos inmunosupresores y composiciones. |
DK1932522T3 (da) * | 2005-10-07 | 2012-07-02 | Kyorin Seiyaku Kk | Terapeutisk middel mod leversygdom indeholdende 2-amino-1,3-propandiolderivat som aktiv bestanddel |
EP1986623A2 (en) * | 2006-01-27 | 2008-11-05 | University Of Virginia Patent Foundation | Method for treatment of neuropathic pain |
TWI389683B (zh) * | 2006-02-06 | 2013-03-21 | Kyorin Seiyaku Kk | A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient |
WO2007092638A1 (en) * | 2006-02-09 | 2007-08-16 | University Of Virginia Patent Foundation | Bicyclic sphingosine 1-phosphate analogs |
CN101506145B (zh) | 2006-08-08 | 2013-05-29 | 杏林制药株式会社 | 氨基醇衍生物以及将它们作为有效成分的免疫抑制剂 |
KR101339976B1 (ko) * | 2006-08-08 | 2013-12-10 | 교린 세이야꾸 가부시키 가이샤 | 아미노인산에스테르 유도체 및 그들을 유효성분으로 하는 s1p 수용체 조절제 |
WO2008064337A2 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Benzocycloheptyl analogs having sphingosine 1-phosphate receptor activity |
EP2097397A1 (en) * | 2006-11-21 | 2009-09-09 | University Of Virginia Patent Foundation | Tetralin analogs having sphingosine 1-phosphate agonist activity |
WO2008064320A2 (en) * | 2006-11-21 | 2008-05-29 | University Of Virginia Patent Foundation | Hydrindane analogs having sphingosine 1-phosphate receptor agonist activity |
CA2699157A1 (en) | 2007-09-10 | 2009-03-19 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
JP2011503046A (ja) * | 2007-11-08 | 2011-01-27 | ファイザー・インク | シクロブチルカルボン酸誘導体 |
GB0725101D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
GB0725104D0 (en) * | 2007-12-21 | 2008-01-30 | Glaxo Group Ltd | Compounds |
TW200946105A (en) | 2008-02-07 | 2009-11-16 | Kyorin Seiyaku Kk | Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient |
WO2009131090A1 (ja) * | 2008-04-21 | 2009-10-29 | 旭化成ファーマ株式会社 | アミノ酸化合物 |
GB0807910D0 (en) * | 2008-04-30 | 2008-06-04 | Glaxo Group Ltd | Compounds |
KR20220084423A (ko) | 2008-07-23 | 2022-06-21 | 아레나 파마슈티칼스, 인크. | 자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[b]인돌-3-일)아세트산 유도체 |
US9149459B2 (en) * | 2008-07-23 | 2015-10-06 | Novartis Ag | Sphingosine 1 phosphate receptor modulators and their use to treat muscle inflammation |
MX2011002149A (es) | 2008-08-27 | 2011-04-05 | Calcimedica Inc | Compuestos que modulan el calcio intracelular. |
SI2342205T1 (sl) * | 2008-08-27 | 2016-09-30 | Arena Pharmaceuticals, Inc. | Substituirani triciklični kislinski derivati kot agonisti S1P1 receptorja, uporabni v zdravljenju avtoimunskih in vnetnih obolenj |
AU2009304598B2 (en) * | 2008-10-17 | 2015-01-29 | Akaal Pharma Pty Ltd | S1P receptors modulators and their use thereof |
JP2012512884A (ja) * | 2008-12-18 | 2012-06-07 | ノバルティス アーゲー | 1−(4−{1−[(e)−4−シクロヘキシル−3−トリフルオロメチル−ベンジルオキシイミノ]−エチル}−2−エチル−ベンジル)−アゼチジン−3−カルボン酸の新規の多形相 |
MX2011006622A (es) * | 2008-12-18 | 2011-07-12 | Novartis Ag | Sales novedosas. |
CA2743397C (en) * | 2008-12-18 | 2017-02-28 | Mathilde Muzerelle | Oxadiazole fused heterocyclic derivatives useful for the treatment of multiple sclerosis |
WO2011017350A2 (en) | 2009-08-04 | 2011-02-10 | Amira Pharmaceuticals, Inc. | Compounds as lysophosphatidic acid receptor antagonists |
UA107360C2 (en) | 2009-08-05 | 2014-12-25 | Biogen Idec Inc | Bicyclic aryl sphingosine 1-phosphate analogs |
US8399451B2 (en) | 2009-08-07 | 2013-03-19 | Bristol-Myers Squibb Company | Heterocyclic compounds |
GB2474120B (en) | 2009-10-01 | 2011-12-21 | Amira Pharmaceuticals Inc | Compounds as Lysophosphatidic acid receptor antagonists |
GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
KR20120098796A (ko) * | 2009-11-24 | 2012-09-05 | 알러간, 인코포레이티드 | 치료적 유용성을 지니는 수용체 조절제로서의 신규한 화합물 |
AR079982A1 (es) * | 2010-01-13 | 2012-03-07 | Sanofi Aventis | Derivados de acido carboxilico heterociclicos que comprenden un anillo de oxazolopirimidina 2,5,7- sustituido., composiciones farmaceuticas y procesos para prepararlos. |
UY33177A (es) * | 2010-01-13 | 2011-08-31 | Sanofi Aventis | Derivados de ácido carboxílico que comprenden un anillo de oxazolopirimidina 2, 5, 7-sustituido |
AR079884A1 (es) * | 2010-01-14 | 2012-02-29 | Sanofi Aventis | Derivados de acido carboxilico heterociclicos que comprenden un anillo de oxazolopirimidina 2,5-sustituida |
CA2784560C (en) * | 2010-01-14 | 2017-12-05 | Sanofi | Carboxylic acid derivatives having a 2,5-substituted oxazolopyrimidine ring |
KR101764607B1 (ko) * | 2010-01-14 | 2017-08-03 | 사노피 | 2,5-치환된 옥사졸로피리미딘 유도체 |
SG10201906876PA (en) | 2010-01-27 | 2019-09-27 | Arena Pharm Inc | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
SG10201501575VA (en) | 2010-03-03 | 2015-04-29 | Arena Pharm Inc | Processes for the preparation of s1p1 receptor modulators and crystalline forms thereof |
US8835470B2 (en) | 2010-04-23 | 2014-09-16 | Bristol-Myers Squibb Company | Mandelamide heterocyclic compounds |
AU2011248579A1 (en) | 2010-04-27 | 2012-11-29 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
WO2011139489A2 (en) | 2010-04-27 | 2011-11-10 | Calcimedica Inc. | Compounds that modulate intracellular calcium |
WO2012009649A1 (en) * | 2010-07-16 | 2012-01-19 | Anderson Gaweco | Mif inhibitors and their uses |
US9079891B2 (en) | 2010-08-27 | 2015-07-14 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
JP5869579B2 (ja) | 2010-09-24 | 2016-02-24 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 置換オキサジアゾール化合物およびそれらのs1p1アゴニストとしての使用 |
JP2013544837A (ja) * | 2010-12-03 | 2013-12-19 | アラーガン インコーポレイテッド | スフィンゴシン−1−リン酸(s1p)受容体モジュレーターとしての新規オキシムアゼチジン誘導体 |
JP2014505025A (ja) * | 2010-12-03 | 2014-02-27 | アラーガン インコーポレイテッド | スフィンゴシン−1−リン酸(s1p)受容体モジュレーターとしての新規アゼチジン誘導体 |
RS57377B1 (sr) | 2010-12-07 | 2018-08-31 | Amira Pharmaceuticals Inc | Policiklični lpa1 antagonist i njegove primene |
BR112013014019A2 (pt) | 2010-12-07 | 2016-09-13 | Amira Pharmaceuticals Inc | antagonistas do receptor do ácido lisofosfatídico e seus usos |
EP3150590B1 (en) * | 2011-02-07 | 2019-10-16 | Biogen MA Inc. | S1p modulating agents |
CN103596947A (zh) | 2011-04-05 | 2014-02-19 | 艾米拉医药股份有限公司 | 用于治疗纤维化、疼痛、癌症和呼吸、过敏性、神经系统疾病或心血管疾病的基于3-或5-联苯-4-基异噁唑的化合物 |
CN103619828A (zh) * | 2011-04-14 | 2014-03-05 | 阿勒根公司 | 作为1-磷酸鞘氨醇受体调节剂的苯基双环甲基胺衍生物 |
US8735402B2 (en) * | 2011-07-07 | 2014-05-27 | Sanofi | Cycloalkyloxycarboxylic acid derivatives |
US8580816B2 (en) * | 2011-07-07 | 2013-11-12 | Sanofi | Carboxylic acid derivatives having an oxazolo[5,4-b]pyridine ring |
KR20140084041A (ko) * | 2011-10-21 | 2014-07-04 | 노파르티스 아게 | S1p 수용체 조절제 또는 효능제에 대한 투여 요법 |
JP6209541B2 (ja) * | 2012-02-03 | 2017-10-04 | ノバルティス アーゲー | N−(4−シクロヘキシル−3−トリフルオロメチル−ベンジルオキシ)−アセトイミド酸エチルエステルの製造方法 |
US9512116B2 (en) | 2012-10-12 | 2016-12-06 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
DK2767532T3 (en) | 2012-12-21 | 2016-09-12 | Nat Inst For Quantum And Radiological Science And Tech | New connection for reproduction of tau protein heavy in the brain. |
WO2014127033A1 (en) * | 2013-02-13 | 2014-08-21 | Allergan, Inc. | Azetidine derivatives as sphingosine 1-phosphate (s1p) receptor modulators |
US9629834B2 (en) | 2013-04-26 | 2017-04-25 | Kyoto University | Medicinal composition for inhibiting formation and/or enlargement of cerebral aneurysm or shrinking same |
CN103408501B (zh) * | 2013-08-14 | 2016-03-09 | 合肥医工医药有限公司 | 苄基嘧啶衍生物、其制备方法及其医药用途 |
EP3046909A4 (en) | 2013-09-17 | 2017-03-29 | Pharmakea, Inc. | Heterocyclic vinyl autotaxin inhibitor compounds |
EP3046905A4 (en) | 2013-09-17 | 2017-03-22 | Pharmakea Inc. | Vinyl autotaxin inhibitor compounds |
EP3049405A4 (en) | 2013-09-26 | 2017-03-08 | Pharmakea Inc. | Autotaxin inhibitor compounds |
CN105793253B (zh) | 2013-11-22 | 2019-08-23 | 法玛克亚公司 | 自分泌运动因子抑制剂化合物 |
WO2015116904A1 (en) | 2014-02-03 | 2015-08-06 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ror-gamma |
WO2016061160A1 (en) | 2014-10-14 | 2016-04-21 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ror-gamma |
US9663515B2 (en) | 2014-11-05 | 2017-05-30 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
US9845308B2 (en) | 2014-11-05 | 2017-12-19 | Vitae Pharmaceuticals, Inc. | Isoindoline inhibitors of ROR-gamma |
CN116850181A (zh) | 2015-01-06 | 2023-10-10 | 艾尼纳制药公司 | 治疗与s1p1受体有关的病症的方法 |
ES2838977T3 (es) | 2015-03-06 | 2021-07-02 | Pharmakea Inc | Inhibidores de la lisil oxidasa fluorada tipo 2 y usos de los mismos |
AU2016268250B2 (en) | 2015-05-27 | 2020-08-27 | Sabre Therapeutics Llc | Autotaxin inhibitors and uses thereof |
ES2929526T3 (es) | 2015-06-22 | 2022-11-29 | Arena Pharm Inc | Sal cristalina de L-arginina del ácido (R)-2-(7-(4-ciclopentil-3-(trifluorometil)benciloxi)-1,2,3,4-tetrahidrociclo-penta[b]indol-3-il)acético para su uso en trastornos asociados al receptor S1P1 |
ES2856931T3 (es) | 2015-08-05 | 2021-09-28 | Vitae Pharmaceuticals Llc | Moduladores de ROR-gamma |
BR112018003776A2 (pt) * | 2015-08-28 | 2018-09-25 | Abbvie Deutschland | compostos heterocíclicos fundidos como moduladores s1p |
RU2018121946A (ru) | 2015-11-20 | 2019-12-23 | Вайтаи Фармасьютиклз, Ллк | Модуляторы ror-гамма |
TW202220968A (zh) | 2016-01-29 | 2022-06-01 | 美商維它藥物有限責任公司 | ROR-γ調節劑 |
US9481674B1 (en) | 2016-06-10 | 2016-11-01 | Vitae Pharmaceuticals, Inc. | Dihydropyrrolopyridine inhibitors of ROR-gamma |
EP3468600A4 (en) * | 2016-06-10 | 2019-11-13 | IO Therapeutics, Inc. | RETINOID COMPOUNDS AND RELECTIVE REXINOIDS OF THE RECEPTOR AND IMMUNE MODULATORS FOR IMMUNOTHERAPY OF CANCER |
JP7079772B2 (ja) | 2016-09-07 | 2022-06-02 | ファーマケア,インク. | リシルオキシダーゼ様2阻害剤の結晶形態および製造方法 |
CA3036062A1 (en) | 2016-09-07 | 2018-03-15 | Pharmakea, Inc. | Uses of a lysyl oxidase-like 2 inhibitor |
CA3053416A1 (en) | 2017-02-16 | 2018-08-23 | Arena Pharmaceuticals, Inc. | Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations |
MA47504A (fr) | 2017-02-16 | 2019-12-25 | Arena Pharm Inc | Composés et méthodes de traitement de l'angiocholite biliaire primitive |
MA49685A (fr) | 2017-07-24 | 2021-04-14 | Vitae Pharmaceuticals Llc | INHIBITEURS DE ROR gamma |
WO2019018975A1 (en) | 2017-07-24 | 2019-01-31 | Vitae Pharmaceuticals, Inc. | INHIBITORS OF ROR GAMMA |
WO2019214681A1 (en) * | 2018-05-09 | 2019-11-14 | Aprinoia Therapeutics Inc. | Heteroaryl compounds and uses thereof |
CN110776450B (zh) * | 2018-07-27 | 2022-09-27 | 广东东阳光药业有限公司 | 一种辛波莫德晶型及其制备方法 |
KR20210074291A (ko) | 2018-09-06 | 2021-06-21 | 아레나 파마슈티칼스, 인크. | 자가면역 및 염증성 장애의 치료에 유용한 화합물 |
CN113072474A (zh) * | 2018-12-06 | 2021-07-06 | 上海济煜医药科技有限公司 | 作为免疫调节剂的化合物及其制备方法和应用 |
US20220017513A1 (en) * | 2018-12-06 | 2022-01-20 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Aromatic ring derivative as immunoregulation and preparation method and application of aromatic ring derivative |
CN111484434A (zh) * | 2019-01-29 | 2020-08-04 | 东莞市东阳光仿制药研发有限公司 | 一种辛波莫德晶型及其制备方法 |
WO2020173346A1 (zh) * | 2019-02-25 | 2020-09-03 | 广东东阳光药业有限公司 | 一种辛波莫德的制备方法 |
CN114728071A (zh) | 2019-11-13 | 2022-07-08 | 新旭生技股份有限公司 | 用于降解tau蛋白聚集体的化合物及其用途 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CH540247A (de) | 1967-04-21 | 1973-09-28 | Ciba Geigy Ag | Verfahren zur Herstellung von heterocyclischen, Asthylendoppelbindungen enthaltenden Verbindungen |
IL109161A0 (en) * | 1993-03-31 | 1994-06-24 | Cell Therapeutics Inc | Amino alcohol derivatives, methods for the preparation thereof, and pharmaceutical compositions containing the same |
AU3325295A (en) * | 1994-08-24 | 1996-03-14 | Eli Lilly And Company | Pyrrolidinyl di-carboxylic acid derivatives as metabotropic glutamate receptor antagonists |
US6110922A (en) * | 1998-12-29 | 2000-08-29 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory and immune-suppressive compounds |
WO2001003739A1 (fr) * | 1999-07-12 | 2001-01-18 | Ono Pharmaceutical Co., Ltd. | Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate |
US20040235794A1 (en) * | 2001-09-04 | 2004-11-25 | Shinji Nakade | Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller |
AU2002363236A1 (en) * | 2001-10-30 | 2003-05-12 | Millennium Pharmaceuticals, Inc. | Compounds, pharmaceutical compositions and methods of use therefor |
CN100500654C (zh) * | 2001-12-14 | 2009-06-17 | 赞塔里斯有限公司 | 作为g-蛋白偶联受体(gpcr)的配体的四氢咔唑衍生物 |
ATE441654T1 (de) * | 2002-01-18 | 2009-09-15 | Merck & Co Inc | Edg-rezeptoragonisten |
WO2003061567A2 (en) | 2002-01-18 | 2003-07-31 | Merck & Co., Inc. | Selective s1p1/edg1 receptor agonists |
DE10207844A1 (de) * | 2002-02-15 | 2003-09-04 | Schering Ag | 1-Phenyl-2-heteroaryl-substituierte Benzimidazolderivate, deren Verwendung zur Herstellung von Arzneimitteln sowie diese Derivate enthaltende pharmazeutische Präparate |
US20030207924A1 (en) * | 2002-03-07 | 2003-11-06 | Xue-Min Cheng | Compounds that modulate PPAR activity and methods of preparation |
RU2318812C2 (ru) * | 2002-04-26 | 2008-03-10 | Ф.Хоффманн-Ля Рош Аг | Производные изохинолина |
JP2007186422A (ja) * | 2004-01-28 | 2007-07-26 | Astellas Pharma Inc | アリールスルフィド誘導体 |
-
2004
- 2004-05-19 JP JP2006533219A patent/JP4575920B2/ja not_active Expired - Fee Related
- 2004-05-19 CA CA2524054A patent/CA2524054C/en not_active Expired - Fee Related
- 2004-05-19 DK DK04752678.5T patent/DK1638551T3/da active
- 2004-05-19 AU AU2004240649A patent/AU2004240649A1/en not_active Abandoned
- 2004-05-19 CN CN2004800132486A patent/CN1791395B/zh active Active
- 2004-05-19 US US10/849,450 patent/US7462629B2/en not_active Expired - Fee Related
- 2004-05-19 BR BRPI0410454-4A patent/BRPI0410454A/pt not_active IP Right Cessation
- 2004-05-19 EP EP04752678A patent/EP1638551B1/en not_active Not-in-force
- 2004-05-19 MX MXPA05012459A patent/MXPA05012459A/es active IP Right Grant
- 2004-05-19 WO PCT/US2004/015701 patent/WO2004103309A2/en active Application Filing
- 2004-05-19 CN CN2004800188602A patent/CN1816544B/zh not_active Expired - Fee Related
- 2004-05-19 PL PL04752678T patent/PL1638551T3/pl unknown
- 2004-05-19 ES ES04752678T patent/ES2379169T3/es active Active
- 2004-05-19 PT PT04752678T patent/PT1638551E/pt unknown
- 2004-05-19 SI SI200431832T patent/SI1638551T1/sl unknown
- 2004-05-19 CN CN2004800131943A patent/CN1787817B/zh not_active Expired - Fee Related
- 2004-05-19 CN CN2004800139502A patent/CN1791592B/zh not_active Expired - Fee Related
- 2004-05-19 US US10/849,079 patent/US7060697B2/en not_active Expired - Fee Related
- 2004-05-19 AT AT04752678T patent/ATE537825T1/de active
-
2005
- 2005-10-11 ZA ZA200508203A patent/ZA200508203B/en unknown
-
2006
- 2006-10-17 HK HK06111346.2A patent/HK1090559A1/xx not_active IP Right Cessation
-
2008
- 2008-07-11 AU AU2008203088A patent/AU2008203088A1/en not_active Abandoned
-
2012
- 2012-03-16 CY CY20121100286T patent/CY1112505T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
CA2524054C (en) | 2012-04-24 |
US7462629B2 (en) | 2008-12-09 |
WO2004103309A2 (en) | 2004-12-02 |
WO2004103309A3 (en) | 2005-03-03 |
MXPA05012459A (es) | 2006-02-22 |
CN1787817A (zh) | 2006-06-14 |
EP1638551A2 (en) | 2006-03-29 |
CA2524054A1 (en) | 2004-12-02 |
US7060697B2 (en) | 2006-06-13 |
CN1791395A (zh) | 2006-06-21 |
EP1638551A4 (en) | 2008-12-31 |
CN1791592B (zh) | 2012-07-04 |
HK1090559A1 (en) | 2006-12-29 |
AU2004240649A1 (en) | 2004-12-02 |
SI1638551T1 (sl) | 2012-04-30 |
CN1816544A (zh) | 2006-08-09 |
CN1791395B (zh) | 2012-09-26 |
CN1791592A (zh) | 2006-06-21 |
PL1638551T3 (pl) | 2012-05-31 |
JP2006528987A (ja) | 2006-12-28 |
US20050009786A1 (en) | 2005-01-13 |
CN1787817B (zh) | 2011-09-07 |
US20050014724A1 (en) | 2005-01-20 |
DK1638551T3 (da) | 2012-04-02 |
JP4575920B2 (ja) | 2010-11-04 |
EP1638551B1 (en) | 2011-12-21 |
ATE537825T1 (de) | 2012-01-15 |
AU2008203088A1 (en) | 2008-08-07 |
CN1816544B (zh) | 2011-06-08 |
BRPI0410454A (pt) | 2006-06-13 |
ES2379169T3 (es) | 2012-04-23 |
ZA200508203B (en) | 2007-02-28 |
PT1638551E (pt) | 2012-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1112505T1 (el) | Ανοσοκατασταλτικες ενωσεις και συνθεσεις | |
TNSN05294A1 (en) | Immunosuppressant compounds and compositions | |
TW200505442A (en) | Immunosuppressant compounds and compositions | |
WO2004113330A8 (en) | Immunosuppressant compounds and compositions | |
WO2005082089A3 (en) | Immunosuppressant compounds and compositions | |
WO2004071442A3 (en) | Novel bicyclic compounds and compositions | |
CY1122238T1 (el) | Νεα 1-ναφθυλ-3-αζαδικυκλο[3.1.0]εξανia: παρασκευη και χρηση για τη θεραπεια νευροψυχιατρικων διαταραχων | |
SE0203713D0 (sv) | Novel compounds | |
TW200716120A (en) | Pyrazolo-pyrimidine derivatives as mGluR2 antagonists | |
TW200611702A (en) | Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders | |
MY153719A (en) | Prokineticin 1 receptor antagonists | |
DE60234616D1 (de) | Substituierte piperidinen mit selektiver bindungsfähigkeit zu histamin h3-rezeptoren | |
MX2007011847A (es) | Derivados de pirimidindiona como antagonistas del receptor de procineticina 2. | |
ATE384727T1 (de) | Pyrimdobenzimidazolderivate und verwendung damit als agonisten oder antagonisten von melanocortinrezeptoren | |
ATE549311T1 (de) | Amino-propanolderivative als modulatoren des sphingosin-1-phosphat-rezeptors | |
ATE407119T1 (de) | Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors | |
TW200801005A (en) | Acetylenic piperazines as metabotropic glutamate receptor antagonists | |
DE60201892D1 (en) | Aminomethylpyrrolochinazoline als thrombinrezeptor-antagonist | |
TW200517382A (en) | Imidazole derivatives | |
ATE417042T1 (de) | Substituierte 2,5-diaminomethyl-1h-pyrrole | |
ATE365556T1 (de) | Verwendung von 3-aza-aoxa-dibenzo(e,h)azulenen zur herstellung von pharmazeutischen formulierung für die behandlung und prävention von erkrankungen und störungen des zentralen nervensystems |